| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bigger isn't always better: the ESMO dose de-intensification guideline framework
|
Shapiro, C.L.
|
|
|
33 |
7 |
p. 672-673
|
artikel
|
| 2 |
Cancer risk in individuals with autism spectrum disorder
|
Liu, Q.
|
|
|
33 |
7 |
p. 713-719
|
artikel
|
| 3 |
Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”
|
Loibl, S.
|
|
|
33 |
7 |
p. 743-744
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
33 |
7 |
p. iii
|
artikel
|
| 5 |
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
|
Filetti, S.
|
|
|
33 |
7 |
p. 674-684
|
artikel
|
| 6 |
HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade
|
Shao, X.M.
|
|
|
33 |
7 |
p. 728-738
|
artikel
|
| 7 |
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
|
Nelli, F.
|
|
|
33 |
7 |
p. 740-742
|
artikel
|
| 8 |
Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
|
Hacker, U.T.
|
|
|
33 |
7 |
p. 685-692
|
artikel
|
| 9 |
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS) ☆
|
Zer, A.
|
|
|
33 |
7 |
p. 720-727
|
artikel
|
| 10 |
Reply to the Letter to the Editor ‘Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer’ by A. Okines and N. Turner
|
Geyer Jr., C.E.
|
|
|
33 |
7 |
p. 739-740
|
artikel
|
| 11 |
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
|
Trapani, D.
|
|
|
33 |
7 |
p. 702-712
|
artikel
|
| 12 |
Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers—ready for prime time?
|
Arulananda, S.
|
|
|
33 |
7 |
p. 669-671
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
33 |
7 |
p. i-ii
|
artikel
|
| 14 |
The age-dependent association of risk factors with pancreatic cancer
|
Yuan, C.
|
|
|
33 |
7 |
p. 693-701
|
artikel
|
Tijdschrift beschrijving